Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials

Autor:	J.C. Lopez-Talavera, Xavier Forns, Guy W. Neff, Ronald D'Amico, Mitchell L. Shiffman, Nancy Reau, Tarik Asselah, Michael B. Bennett, Vinod K. Rustgi, Ramon Planas Vila, Marcos C. Pedrosa, Greg Ball
Rok vydání:	2015
Předmět:	Dasabuvir Hepatology business.industry Ribavirin Gastroenterology Pharmacology Ombitasvir chemistry.chemical_compound chemistry Paritaprevir Concomitant Medicine In patient business medicine.drug
Zdroj:	American Journal of Gastroenterology. 110:S851-S852
ISSN:	0002-9270
DOI:	10.14309/00000434-201510001-02019
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e04047db92d10b8cc375a18c5273f1c3 https://doi.org/10.14309/00000434-201510001-02019 Zobrazit plný text záznamu